Wall Street analysts expect that Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) will report ($0.72) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Aadi Bioscience’s earnings, with the lowest EPS estimate coming in at ($0.77) and the highest estimate coming in at ($0.66). Aadi Bioscience posted earnings per share of ($1.35) in the same quarter last year, which indicates a positive year over year growth rate of 46.7%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Aadi Bioscience will report full-year earnings of ($2.85) per share for the current year, with EPS estimates ranging from ($3.22) to ($2.26). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.97) per share, with EPS estimates ranging from ($3.51) to ($2.30). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover Aadi Bioscience.
Aadi Bioscience (NASDAQ:AADI – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.02. During the same period in the previous year, the firm posted ($0.90) EPS.
AADI traded up $0.49 during trading hours on Thursday, reaching $14.35. 71,306 shares of the company’s stock traded hands, compared to its average volume of 118,402. The firm has a market capitalization of $300.52 million, a PE ratio of -1.20 and a beta of 1.57. Aadi Bioscience has a 52-week low of $11.00 and a 52-week high of $49.80. The firm has a 50-day moving average price of $16.36 and a 200 day moving average price of $19.89.
In other Aadi Bioscience news, insider Neil Desai sold 3,550 shares of the stock in a transaction dated Friday, March 18th. The shares were sold at an average price of $20.07, for a total transaction of $71,248.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.10% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in AADI. VR Adviser LLC bought a new stake in shares of Aadi Bioscience in the 3rd quarter valued at about $44,919,000. BVF Inc. IL bought a new stake in shares of Aadi Bioscience in the 3rd quarter valued at about $33,689,000. Rock Springs Capital Management LP bought a new stake in shares of Aadi Bioscience in the 3rd quarter valued at about $22,459,000. RTW Investments LP bought a new stake in shares of Aadi Bioscience in the 3rd quarter valued at about $21,336,000. Finally, State Street Corp boosted its holdings in shares of Aadi Bioscience by 72.0% in the 1st quarter. State Street Corp now owns 535,578 shares of the company’s stock valued at $9,089,000 after buying an additional 224,178 shares in the last quarter. 62.56% of the stock is currently owned by institutional investors and hedge funds.
Aadi Bioscience Company Profile (Get Rating)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.
- Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.